Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gp high cells and correlates with HIV-1 viral load

  • Minuesa, Gerard|||0000-0001-9911-8428
  • Arimany-Nardi, Cristina
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Moltó Marhuenda, José
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Pastor-Anglada, Marçal|||0000-0003-3712-1773
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
To evaluate the role of P-glycoprotein (P-gp) and multidrug-resistant-protein 1 (MRP1) on raltegravir intracellular drug disposition in CD4+ T cells, investigate the effect of HIV-1 infection on P-gp expression and correlate HIV-1 viraemia with P-gp activity in primary CD4+ T cell subsets. The cellular accumulation ratio of [ 3 H]raltegravir was quantified in CD4+ T cell lines overexpressing either P-gp (CEM-P-gp) or MRP1 (CEM-MRP1) and in primary CD3+CD4+ T cells with high (P-gp high) and low P-gp activity (P-gp low); inhibition of efflux transporters was confirmed by the intracellular retention of calcein-AM. The correlation of P-gp activity with HIV-1 viraemia was assessed in naive and memory T cell subsets from 21 HIV-1-infected treatment-naive subjects. [ 3 H]Raltegravir cellular accumulation ratio decreased in CEM-P-gp cells (P < 0.0001). XR9051 (a P-gp inhibitor) and HIV-1 PIs reversed this phenomenon. Primary CD4+P-gp high cells accumulated less raltegravir (38.4% ± 9.6%) than P-gp low cells, whereas XR9051 also reversed this effect. In vitro HIV-1 infection of PBMCs and stimulation of CD4+ T cells increased P-gp mRNA and P-gp activity, respectively, while primary CD4+P-gp high T cells sustained a higher HIV-1 replication than P-gp low cells. A significant correlation between HIV-1 viraemia and P-gp activity was found in different CD4+ T cell subsets, particularly memory CD4+ T cells (r = 0.792, P < 0.0001). Raltegravir is a substrate of P-gp in CD4+ T cells. Primary CD4+P-gp high T cells eliminate intracellular raltegravir more readily than P-gp low cells and HIV-1 viraemia correlates with P-gp overall activity. Specific CD4+P-gp high T cell subsets could facilitate the persistence of viral replication in vivo and ultimately promote the appearance of drug resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue

  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Navarro, Jordi|||0000-0002-7187-0367
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Esteve, Maria|||0000-0001-7716-0027
  • Manyè, Josep
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Salgado, Maria|||0000-0003-1551-7216
  • Martinez Picado, Javier
Background. The implementation of successful strategies to achieve an HIV cure has become a priority in HIV research. However, the current location and size of HIV reservoirs is still unknown since there are limited tools to evaluate HIV latency in viral sanctuaries such as gut-associated lymphoid tissue (GALT). As reported in the so called "Boston Patients", despite undetectable levels of proviral HIV-1 DNA in blood and GALT, viral rebound happens in just few months after ART interruption. This fact might imply that current methods are not sensitive enough to detect residual reservoirs. Showing that, it is imperative to improve the detection and quantification of HIV-1 reservoir in tissue samples. Herein, we propose a novel nonenzymatic protocol for purification of Lamina Propria Leukocytes (LPL) from gut biopsies combined to viral HIV DNA (vDNA) quantification by droplet digital PCR (ddPCR) to improve the sensitivity and accuracy of viral reservoir measurements (LPL-vDNA assay). Methods. Endoscopic ileum biopsies were sampled from 12 HIV-1-infected cART- suppressed subjects. We performed a DTT/EDTA-based treatment for epithelial layer removal followed by non-enzymatic disruption of the tissue to obtain lamina propria cell suspension (LP). CD45+ cells were subsequently purified by flow sorting and vDNA was determined by ddPCR. Results. vDNA quantification levels were significantly higher in purified LPLs (CD45+) than in bulk LPs (p<0.01). The levels of vDNA were higher in ileum samples than in concurrent PBMC from the same individuals (p = 0.002). As a result of the increased sensitivity of thispurification method, the Poisson 95% confidence intervals of the vDNA quantification data from LPLs were narrower than that from bulk LPs. Of note, vDNA was unambiguously quantified above the detection limit in 100% of LPL samples, while only in 58% of bulk LPs. Conclusion. We propose an innovative combined protocol for a more sensitive detection of the HIV reservoir in gut-associated viral sanctuaries, which might be used to evaluate any proposed eradication strategy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen, A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals

  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Navarro, Jordi|||0000-0002-7187-0367
  • Jimenez, Montse
  • Rutsaert, Sofie
  • Urrea, Víctor|||0000-0002-2577-856X
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Torrella Domingo, Adriana|||0000-0003-1848-5096
  • De Clercq, Laura
  • Ribas, Bibiana Planas
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Salgado, Maria|||0000-0003-1551-7216
  • Vandekerckhove, Linos|||0000-0002-8600-1631
  • Blanco, Julià|||0000-0002-2225-0217
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
Optimization of combination antiretroviral therapy (cART) can impact the human immunodeficiency virus (HIV) reservoir. We evaluated the effect on the HIV reservoir in peripheral blood and ileum biopsies in patients switching from boosted protease inhibitor (PI/r)-based therapy to dolutegravir (DTG)-based therapy. Impact of Integrase-inhibitor DOlutegravir On the viral Reservoir (INDOOR) is a phase 4 open-label clinical trial that randomly included 42 HIV type 1-infected individuals on effective cART: 20 who switched from PI/r-based to DTG-based cART (switch group), and 22 who remained in PI/r-based regimens (control group). We analyzed blood and ileum biopsies to quantify episomal, total, and integrated HIV DNA, cell-associated HIV RNA, residual plasma viremia, T-cell subsets, cell activation, and inflammation markers. There were no related adverse events or treatment discontinuations due to drug intolerance. The HIV reservoir was consistently larger in ileal than in peripheral CD4 + T cells in both groups (P <.01). Residual viremia in plasma decreased in the switch group (P =.03). However, we did not observe significant longitudinal changes in low-level viral replication, total and integrated HIV reservoir, HIV transcription, T-cell maturation subsets, immunoactivation markers, inflammatory soluble proteins, or cellular markers of latently infected cells. The INDOOR study is the first evaluation of changes in HIV reservoir size in ileum biopsies and in peripheral blood in individuals switched from PI/r- to DTG-based cART. Although this switch was safe and well tolerated, it had no impact on a large array of immunological and inflammatory markers or on HIV reservoir markers in peripheral or in ileal CD4 + T cells. EudraCT 2014-004331-39. INDOOR evaluated the effect of switching from boosted protease inhibitor- to dolutegravir-based antiretroviral therapy on the HIV reservoir in peripheral blood and ileum. Residual plasma viremia and soluble CD14 levels decreased, but low-level HIV replication, the HIV reservoir, and immune activation remained unaffected.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression

  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Urrea, Víctor|||0000-0002-2577-856X
  • Dalmau, Judith|||0000-0001-7513-3711
  • Lopez, Miguel
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Ouchi, Dan|||0000-0002-8630-152X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Passaes, Caroline|||0000-0002-0813-2521
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Saez-Cirion, Asier
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Esteller, M.|||0000-0003-4490-6093
  • Berdasco, Maria|||0000-0002-6750-0400
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
BACKGROUND: Human genetic variation-mostly in the human leukocyte antigen (HLA) and C-C chemokine receptor type 5 (CCR5) regions-explains 25% of the variability in progression of human immunodeficiency virus (HIV) infection. However, it is also known that viral infections can modify cellular DNA methylation patterns. Therefore, changes in the methylation of cytosine-guanine (CpG) islands might modulate progression of HIV infection. METHODS: In total, 85 samples were analyzed: 21 elite controllers (EC), 21 subjects with HIV before combination antiretroviral therapy (cART) (viremic, 93 325 human immunodeficiency virus type 1 [HIV-1] RNA copies/mL) and under suppressive cART (cART, median of 17 months, <50 HIV-1 RNA copies/mL), and 22 HIV-negative donors (HIVneg). We analyzed the methylation pattern of 485 577 CpG in DNA from peripheral CD4+ T lymphocytes. We selected the most differentially methylated gene (TNF) and analyzed its specific methylation, messenger RNA (mRNA) expression, and plasma protein levels in 5 individuals before and after initiation of cART. RESULTS: We observed 129 methylated CpG sites (associated with 43 gene promoters) for which statistically significant differences were recorded in viremic versus HIVneg, 162 CpG sites (55 gene promoters) in viremic versus cART, 441 CpG sites (163 gene promoters) in viremic versus EC, but none in EC versus HIVneg. The TNF promoter region was hypermethylated in viremic versus HIVneg, cART, and EC. Moreover, we observed greater plasma levels of TNF in viremic individuals than in EC, cART, and HIVneg. CONCLUSIONS: Our study shows that genome methylation patterns vary depending on HIV infection status and progression profile and that these variations might have an impact on controlling HIV infection in the absence of cART.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals, Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)

  • Mothe, Beatriz|||0000-0001-9975-407X
  • Rosás-Umbert, Miriam|||0000-0002-2850-6586
  • Coll, Pep
  • Manzardo, Christian
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Miranda, Cristina
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • López, Miriam
  • Alarcón-Soto, Yovaninna|||0000-0002-9977-8634
  • Melis, Guadalupe Gómez
  • Langohr, Klaus|||0000-0001-7075-9192
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Toro, Jessica
  • Ruiz, Irene
  • Rovira, Cristina
  • Carrillo, Antonio
  • Meulbroek, Michael
  • Crook, Alison
  • Wee, Edmund G.
  • Miró, José M.|||0000-0001-8057-7755
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Valle, Marta|||0000-0002-3515-251X
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Hanke, Tomáš|||0000-0002-6076-9546
  • Brander, Christian|||0000-0002-0548-5778
  • Moltó, José|||0000-0003-4564-1963
Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label, single-arm, phase I clinical trial, enrolling 15 early-treated HIV-1-infected individuals, testing the combination of the histone deacetylase inhibitor romidepsin as a latency-reversing agent and the MVA.HIVconsv vaccine. Romidepsin treatment resulted in increased histone acetylation, cell-associated HIV-1 RNA, and T-cell activation, which were associated with a marginally significant reduction of the viral reservoir. Vaccinations boosted robust and broad HIVconsv-specific T cells, which were strongly refocused toward conserved regions of the HIV-1 proteome. During a monitored ART interruption phase using plasma viral load over 2,000 copies/ml as a criterium for ART resumption, 23% of individuals showed sustained suppression of viremia up to 32 weeks without evidence for reseeding the viral reservoir. Results from this pilot study show that the combined kick&kill intervention was safe and suggest a role for this strategy in achieving an immune-driven durable viremic control.